Association between sodium-glucose cotransporter 2 inhibitor therapy and outcome in 1,775 congenital heart disease patients – Application of an active comparator new user design
Heart failure (HF) is highly prevalent in congenital heart disease (CHD), driving morbidity and mortality. Evidence supporting sodium–glucose cotransporter-2 inhibitors (SGLT2i) in CHD remains scarce, largely due to the absence of randomised trials in this specific patient group. To evaluate the prognostic...